Combining the HSP90 Inhibitor, AT13387, with Vemurafenib Delays the Emergence of Resistance in a Preclinical Model of BRAFV600E Mutant Melanoma

被引：0
|
作者：
Smyth, T. [1 ]
Lewis, J. [1 ]
Thompson, N. [1 ]
Lyons, J. [1 ]
Azab, M. [1 ]
Wallis, N. [1 ]
机构：
[1] Astex Pharmaceut, Cambridge, England
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [1] The HSP90 inhibitor, onalespib (AT13387), delays the emergence of resistance to erlotinib in an EGFR-driven xenograft model
    Courtin, Aurelie
    Smyth, Tomoko
    Hearn, Keisha
    Lyons, John
    Thompson, Neil
    Wallis, Nicola G.
    [J]. CANCER RESEARCH, 2015, 75
  • [2] AT13387, an HSP90 inhibitor, is effective in both vemurafenib-sensitive and -resistant melanoma models
    Rodriguez-Lopez, Ana M.
    Smyth, Tomoko
    Curry, Jayne
    Graham, Brent
    McMenamin, Rachel
    Lyons, John
    Thompson, Neil
    Wallis, Nicola
    [J]. CANCER RESEARCH, 2012, 72
  • [3] Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
    Smyth, Tomoko
    Paraiso, Kim H. T.
    Hearn, Keisha
    Rodriguez-Lopez, Ana M.
    Munck, Joanne M.
    Haarberg, H. Eirik
    Sondak, Vernon K.
    Thompson, Neil T.
    Azab, Mohammad
    Lyons, John F.
    Smalley, Keiran S. M.
    Wallis, Nicola G.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) : 2793 - 2804
  • [4] The HSP90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance
    Rodriguez-Lopez, Ana
    Smyth, Tomoko
    McMenamin, Rachel
    Lyons, John
    Thompson, Neil
    Lock, Victoria
    Taverna, Pietro
    Corringham, Robert
    Wallis, Nicola
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [5] COMBINING THE HSP90 INHIBITOR, AT13387, WITH CRIZOTINIB IMPROVES RESPONSE IN AN ALK-POSITIVE MODEL OF NSCLC
    Smyth, Tomoko
    Munck, Joanne
    Rodriguez-Lopez, Ana
    Mcmenamin, Rachel
    Thompson, Neil
    Azab, Mohammad
    Lyons, John
    Wallis, Nicola G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S163 - S163
  • [6] Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program
    Kang, Min H.
    Reynolds, C. Patrick
    Houghton, Peter J.
    Alexander, Denise
    Morton, Christopher L.
    Kolb, E. Anders
    Gorlick, Richard
    Keir, Stephen T.
    Carol, Hernan
    Lock, Richard
    Maris, John M.
    Wozniak, Amy
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2012, 59 (01) : 185 - 188
  • [7] BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
    Kulkarni, Atul
    Al-Hraishawi, Husam
    Simhadri, Srilatha
    Hirshfield, Kim M.
    Chen, Suzie
    Pine, Sharon
    Jeyamohan, Chandrika
    Sokol, Levi
    Ali, Siraj
    Teo, Man Lung
    White, Eileen
    Rodriguez-Rodriguez, Lorna
    Mehnert, Janice M.
    Ganesan, Shridar
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (18) : 5631 - 5638
  • [8] The HSP90 inhibitor, AT13387, overcomes resistance to crizotinib and second generation ALK inhibitors
    Courtin, A.
    Smyth, A.
    Hearn, K.
    Martins, V.
    Lewis, J.
    Thompson, N.
    Lyons, J.
    Wallis, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 168 - 168
  • [9] Inhibition of Tumour Growth in a Pancreatic Cancer Xenograft Model by AT13387, an HSP90 Inhibitor
    Shaw, E.
    Thomas, A.
    Ghaneh, P.
    Greenhalf, W.
    Davies, M.
    Costello, E.
    Gibbs, F.
    Lyons, J.
    Neoptolemos, J. P.
    Sibson, D. R.
    [J]. PANCREAS, 2011, 40 (08) : 1353 - 1353
  • [10] The HSP90 Inhibitor, AT13387, Is Effective In Mutant EGFR And ALK-positive NSCLC Models.
    Wallis, N. G.
    Smyth, T.
    Rodriguez-Lopez, A.
    McMenamin, R.
    Lock, V.
    Curry, J.
    Graham, B.
    Lyons, J.
    Thompson, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S254 - S254
12345